Roquefort Therapeutics STAT-6 siRNA Shows Efficacy in Experimental Model, Pursues Out-Licensing Deal

Roquefort Therapeutics CEO Ajan Reginald joined Steve Darling from Proactive to share the promising results of their STAT-6 siRNA program, demonstrating efficacy in a validated in vitro model of immunological disease. siRNA therapeutics represent an innovative class of medicines that utilize RNA interference to disrupt gene messaging and downregulate target proteins. Roquefort Therapeutics’ siRNA specifically targets STAT-6, a key transcription factor involved in signaling pathways that mediate Type 2 inflammatory responses, driven by cytokines IL-4 and IL-13. Reginald highlighted that the siRNA significantly reduced STAT-6 levels compared to multiple controls in preliminary experiments, confirming the potential of this approach for inflammation and immunology. Further methodology and results will be disclosed at a future scientific conference or through a peer-reviewed publication. The company is actively seeking an out-licensing deal with Big Pharma for its STAT-6 siRNA program. The positive results from these recent experiments, combined with previous positive oncology data, bolster the program’s appeal to potential partners. Roquefort Therapeutics plans to keep the market updated on the progress of these negotiations. #proactiveinvestors #roqueforttherapeuticsplc #lse #roq #drugdiscovery #pharma #bigpharma #sirna #stat-6 #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews